Raymond Wei Liu

20220372101, Nov 24, 2022

Sep 23, 2020

17/763110

- Oakland CA, US
Raymond LIU - Oakland CA, US
Iowis ZHU - Oakland CA, US

C07K 14/705
C07K 14/47
C07K 16/28
A61P 35/02
A61K 35/17
A61K 45/06
A61K 39/395
A61K 38/17
C07K 14/575
A61K 38/22
A61P 35/00

The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcription in a ligand-dependent manner. The new receptors provide a selectable degree of noise, expression level, and signal to noise ratio. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions or diseases, such as cancers.

20220356225, Nov 10, 2022

Sep 23, 2020

17/763122

- Oakland CA, US
- Boston MA, US
Raymond LIU - San Francisco CA, US
Ahmad S. KHALIL - Boston MA, US
Divya ISRANI - Boston MA, US

C07K 14/705
C07K 16/28
C07K 14/725
A61K 35/17
C12N 5/0783

The present disclosure generally relates to, inter alia, a new class of chimeric Notch receptors containing a synthetic zinc finger transcriptional effector (synZTE) module, engineered to modulate gene expression and cellular activities in a ligand-dependent manner. The new Notch receptors surprisingly retain the ability to transduce signals in response to ligand binding despite that the Notch extracellular subunit, which includes the negative regulatory region previously believed to be essential for the functioning of Notch receptors, is partly or completely deleted. In addition, the synZTE is designed to bind orthogonal DNA target sequences in target organisms which in turn facilitates precise regulation of therapeutic gene expression with minimal off-target activity. Also provided are compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for treatment of various health conditions.

20220348628, Nov 3, 2022

Sep 23, 2020

17/762687

- Oakland CA, US
Raymond LIU - San Francisco CA, US
Iowis ZHU - San Francisco CA, US

C07K 14/705
C07K 16/30
C07K 16/28
C07K 16/22
A61K 35/17
A61K 45/06

The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner Particularly, the new receptors, even though derived from Notch and Robo, do not require the Notch or Robo regulatory regions previously believed to be necessary for the functioning of the receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions such as diseases (e.g., cancers).

20220348677, Nov 3, 2022

Sep 23, 2020

17/763116

- Oakland CA, US
Raymond LIU - Oakland CA, US
Iowis ZHU - Oakland CA, US

C07K 16/28
C07K 14/47

The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. In particular, the new receptors contain a heterologous transmembrane domain comprising at least one γ-secretase site. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions or diseases, such as cancers.

20220340637, Oct 27, 2022

Sep 23, 2020

17/762685

- Oakland CA, US
Raymond LIU - San Francisco CA, US
Iowis ZHU - San Francisco CA, US

C07K 14/705
C07K 16/28
A61K 35/17
A61P 35/02
A61K 45/06
A61K 39/395
A61K 38/17

The present disclosure generally relates to, inter alia, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. In addition, the new receptors described herein incorporate a flexible polypeptide connector region disposed between the extracellular ligand-binding domain (ECD) and the transmembrane domain (TMD) which facilitates optimizing the stiffness/flexibility of the chimeric polypeptides to achieve a desired activity. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions such as diseases (e.g., cancers).

20210268024, Sep 2, 2021

Mar 30, 2021

17/217618

- Oakland CA, US
Raymond Liu - San Francisco CA, US
Iowis Zhu - San Francisco CA, US

A61K 35/17
A61P 35/00
C07K 16/28
C07K 14/705
C07K 16/32

The present disclosure generally relates to, inter alia, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. In addition, the new receptors described herein incorporate an extracellular oligomerization domain to promote oligomer formation of the chimeric receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions such as cancers.

20210246186, Aug 12, 2021

Mar 30, 2021

17/217635

- Oakland CA, US
Raymond Liu - San Francisco CA, US
Iowis Zhu - San Francisco CA, US

C07K 14/705
C12N 5/0783
A61K 35/17

The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions or diseases, such as cancers.